GoggleDocs

Albuminuria: The CKM biomarker we’re overlooking❗️ 💡The best risk stratifying biomarker 🔹 Even UACR <3.4 mg/mmol = ⤴️ #CVD, #CKD & mortality risk 🔸 Signals early endothelial dysfunction across HTN, #T2D, #HF & #MASLD 🔹 Yet 💧screening rates low, esp. in primary care 🔸…

💙 Early heart failure detection in diabetes. In >116,000 adults with T1D or T2D 🩸 without known HF, higher natriuretic peptide (BNP/NT-proBNP) levels strongly predicted future HF or death over 7 years. 📊 NT-proBNP > 300 pg/mL → 🫀 4.5× higher risk in T1D 💔 3.6× higher risk…

Liraglutide in Acute Minor Ischemic Stroke or High-Risk TIA With T2DM Whilst the phrasing of results is a bit unorthodox, I’ve always considered incretins an important intervention for such patients timing-wise jamanetwork.com/journals/jamai… @kamleshkhunti @GoggleDocs @mmamas1973

🧬 Autoimmunity & Type 1 Diabetes Risk 📊 Cohort: 1.43 million Israeli adolescents (ages 16–19) • 2.7% had autoimmune disease (AITD or Celiac) • Follow-up ≈ 15.8 million person-years 🔥 Results: · Incident T1D risk ⬆ 2.2-fold with autoimmunity · Strongest signals: 🦋…

🧬💊 SGLT2 Inhibitors & Autoimmune Disease Risk 🇰🇷 South Korea 📈 2,032,157 adults with T2D ✨ ↓ Autoimmune rheumatic disease risk by 11% 💡 SGLT2 inhibitors may offer immune-modulating benefits beyond glucose & heart protection Need for more trials 😃 #SGLT2i #Diabetes…

💖 Even a few steps per day is beneficial! In 13,547 older women (mean age 72), walking ≥4,000 steps/day just 1–2 days/week lowered: 🔹 All-cause mortality by 26% 🔹 CVD risk by ~27% Walking ≥3 days/week cut mortality risk by 40%! More steps = greater benefit, but every bit…

💊 SGLT2 inhibitors & phimosis risk in men with T2D 📍 Danish cohort study (2016–2021) comparing SGLT2i vs GLP-1RA initiators 📊 1-year phimosis risk: 0.9% vs 0.5% → RR 1.88 (95% CI 1.43–2.47) 📊 8-year risk: 4.8% vs 3.6% → RR 1.36 (95% CI 1.14–1.61) ⚠️ Risk remains…

🚨 Spinal cord stimulation⚡️ ⤵️ 💔 &☠️⁉️🚨 🔹 Propensity match cohort study (n=6074) with painful diabetic neuropathy over 3y 🔸 SCS vs dual gabapentinoid+duloxetine ⤵️MACE by 43% ⤵️☠️by 51% ⚠️ retrospective observational data risk of selection bias 👉 Impressive signals…

Surprise, or clinical validation of previous findings? 2009. Liraglutide reduces infarct size and death independent of weight loss or glycemic control in mice diabetesjournals.org/diabetes/artic… HARMONY Outcomes Trial 2018 Lancet Albiglutide produces 22% reduction in MACE, <1% weight loss

🚨SELECT trial surprise🚨 💉 Semaglutide ⤵️cardiovascular events 20% regardless of wt loss. 🔸👫losing <5% had same CV benefit as those losing >5%. 🔹Only 33% of benefit explained by waist circ. changes. 👉Reframes GLP-1s from weight loss drugs to CV disease modifiers. 🔗…

💊 SGLT2i in the very elderly with heart failure Mean age 90 yrs! Mean Charlson Comorbidity Index score was 8.2 📊 Prospective multicentre study • ↓ All-cause mortality: HR 0.67 • ↓ HF rehospitalisation: HR 0.64 • ↓ Composite outcome: HR 0.60 ✅ Benefits…

🔍 Cross-sectional analysis of CGM prescribing across ICBs & PCNs, examining ethnicity & deprivation. 📈 Findings: • Mean CGM prescribing: 4.87 / 1000 people(range 0.26–11.59) • Lower CGM use in areas with ↑ Afro-Caribbean & South Asian populations ⚠️ Major ethnic and…

Some basics to remember!!! And it may help save a life Check for #T1Diabetes at the slightest suspicion Please cascade to colleagues and keep at improving awareness Thank you (Poster via @DiabetesUK) #gbdoc 💙

Data is always fascinating to observe. Here is what the #NHS is doing as regards #Tirzapetide aka #Mounjaro (26 million £ spend in July 25) Would be interesting to see the following: 1. Who is getting it? Is this only those with #T2D or beyond? 2. What are sales like in…

Thank you @SouthAsianHF for the kind invite @docwas And an absolute pleasure to talk about health inequalities, progress made in #T1D and work to be done in #T2D @kamleshkhunti @scelee1 With a mention of the MWRES work with @RaoMala It can be done. THAT’S the message 😊

🩺 SGLT2 inhibitors for primary prevention in T2 Diabetes (T2D) Can SGLT2i reduce first-time cardiovascular (CV) events in people without prior heart disease? 🇹🇼 New nationwide cohort (Taiwan) 📊 Mean follow-up ≈ 2.8 years ❤️ In patients with hypertension SGLT2i vs DPP-4i ↓…

⚡️ Multiple long term conditions (MLTC or Multimorbidity) & Sudden Cardiac Death (SCD) 📊 cohort (2,598 men, aged 42–61, 28 yrs follow-up): • 296 SCDs recorded • MLTC (≥2 chronic conditions) → ~2× higher SCD risk (HR 1.97) • Risk ⬆️ with number of conditions: · 2–3: HR…

🔥 Incretin therapies & liver outcomes in T2 diabetes Real-world EHR study (150M+ pateints): 📉 Tirzepatide↓ risk of major adverse liver outcomes (MALO) by 47%(HR 0.53) 📉 Semaglutide↓ risk by 19% (HR 0.81) ⚪️ Liraglutide - no significant benefit ➡️ Benefit driven by ↓…

As per recent data re #NHS? Waiting Lists are up; A&E markers on 12 hour waits not moving; strikes on the horizon; doctors without jobs; ICBs in flux over roles, mergers, Huge concerns over finances plus potential for medications etc to cost more etc etc That is the present…

🚨 Very High Prevalence of Non-optimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease Before CHD, HF or stroke, >99% had ≥1 nonoptimal risk factor (BP, cholesterol, glucose, smoking) ➡️ Challenges the idea that CVD often occurs “without risk…

🚨 Pregnancy & Heart Health: 19-Year Trend ❤️ Maternal CVD ↑ from 1% → 7% ⚠️ CV complications ↑ from 11% → 13% 🩺 Higher risk in those with diabetes, hypertension, or pre-existing CVD Pregnancy is a critical window for cardiovascular prevention #CardioObstetrics…